The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.
INTRODUCTION
Streptococcus pneumoniae is an encapsulated bacterium that accounts for the majority of bacterial upper and lower respiratory tract infections and is responsible for millions of deaths each year (Feikin et al., 2000; World Health Organization, 2007) . To protect from the morbidity and mortality caused by S. pneumoniae, pneumococcal carbohydrate vaccines were introduced. Vaccine-induced immunoprotection against encapsulated bacteria is primarily mediated by opsonophagocytic antibodies that bind capsular polysaccharides (CPSs) (Song et al., 2013) . CPS antigens are thymus-independent type 2 antigens and often induce low-affinity antibodies with a restricted isotype distribution and evoke only insignificant B cell memory particularly in the very young and the very old (Mond et al., 1995) . To overcome these deficiencies of polysaccharide vaccines, current conjugate vaccines against pneumococci consist of CPSs that are chemically linked to a carrier protein to form glycoconjugates that promote T cell-dependent antibody responses and long-lasting memory (Pletz et al., 2008) . Only a minority of the more than 90 S. pneumoniae serotypes cause the vast majority of pneumococcal infections (Gruber et al., 2012) . Seven serotypes were included in the first S. pneumoniae glycoconjugate vaccine (PCV7) that drastically reduced invasive pneumococcal disease. However, the overall efficacy of PCV7 was partly offset by serotype replacement and subsequent increase in invasive pneumococcal disease caused by nonvaccine serotypes (Hicks et al., 2007; Yildirim et al., 2012) . Serotypes that emerged after the introduction of PCV7 have been included in the current anti-pneumococcal glycoconjugate vaccine (PCV13, Prevnar 13) (Gruber et al., 2012) . S. pneumoniae serotype 3 (ST3) causes invasive pneumococcal infections in adults and is covered by PCV13. ST3 strains are often used in experimental models of pneumonia, meningitis, and otitis media owing to their high virulence in animals (Chiavolini et al., 2008) and as a model to study protective immunogenic properties of candidate vaccines (Jakobsen et al., 1999a (Jakobsen et al., , 1999b . The ST3 glycoconjugates contained in PCV13 are of rather low efficacy leading to hyporesponsiveness (Gruber et al., 2012; Song et al., 2013) . ST3 CPS conjugates showed an atypical immunogenicity and boostability pattern. PCV13 is insufficient at limiting acute otitis media infections caused by ST3. Altered CPS expression, capsule thickness, and an impaired booster response may all contribute to the low efficacy of ST3 conjugates (Poolman et al., 2009) .
Current glycoconjugate vaccine preparations contain CPS isolated from fermentation broths after inactivation of the cultured pathogen (Schumann et al., 2013) . The resulting products are ill-defined and may generate artificial neoglycotopes when subjected to processing steps such as depolymerization and activation prior to conjugation (Schumann et al., 2013) . Polysaccharides contain multiple coupling sites and consist of a complex glycan pool of different chain lengths. Contamination with other highly immunogenic broth components such as cell wall polysaccharide is sometimes observed and may lead to hyporesponsiveness. Glycoconjugates of synthetic oligosaccharides are a promising alternative to vaccines derived from isolated glycans (Astronomo and Burton, 2010; Anish et al., 2014) . The immunogenic properties of synthetic glycoconjugates can be optimized by designing antigenic structures based on the binding specificities and structural features of protective antibodies. Synthetic oligosaccharides based on ST3 CPS repeating units have been shown to protect immunized mice against lethal systemic challenge with ST3 pneumococci via non-mucosal routes (Benaissa-Trouw et al., 2001) . It remains unclear whether glycoconjugates containing synthetic oligosaccharide can confer protection against bacterial pneumonia, the most common form of severe pneumococcal infection. Moreover, the structural characteristics of ST3 CPS antigenic components that confer protection or drive non-specific responses are still poorly understood.
Here, we define a highly immunogenic tetrasaccharide glycotope based on the disaccharide repeating unit of ST3 CPS ( Figure 1 ). We show that synthetic oligosaccharide-based glycoconjugates are immunoprotective against experimental pneumonia caused by transnasal infection with ST3 strain PN36. Antigenic specificities of anti-ST3 antibodies were dissected by glycan arrays displaying oligosaccharide fragments including the ST3 CPS repeating unit. An ST3 oligosaccharide antigen lead for vaccine development was identified by combining organic synthesis, glycan arrays, glycoconjugation, in vivo vaccination, and challenge experiments.
RESULTS AND DISCUSSION Synthesis of ST3 Oligosaccharides
ST3 glycans ranging from monoto tetrasaccharides containing different terminal sugars (Figure 1 and 1-7) were prepared to include an alkylamine linker at the reducing end for glycan array immobilization and conjugation to carrier proteins ( Figure 2 ). Two differentially protected glucose building blocks (8 and 9) were prepared using previously established methods (Hällgren and Widmalm, 1993; Eichler et al., 1997; Yu and Ensley, 2003) . Selective activation of glycosyl trichloroacetimidate 8 and coupling with thioglycoside 9 yielded β-linked disaccharide 10 (Figure 2 ) (Yu and Ensley, 2003; Mo et al., 2009) . Placement of the ethanolamine linker 11 by thioglycoside activation and silyl removal provided disaccharide acceptor 12 (Beshore and Dinsmore, 2002) . Glycosylation of disaccharides 10 and 12 using Niodosuccinimide/trifluoromethanesulfonic acid furnished the fully protected tetrasaccharide 13 after Trisbuffered saline removal and benzoylation. Benzylidene cleavage followed by selective oxidation of the primary C6 hydroxyl groups resulted in the dicarboxylic acid derivative 14. Removal of all protective groups under Zemplén conditions followed by hydrogenation furnished tetrasaccharide 1. Overall yield was 13% from building blocks 8 and 9. Glycans 2a and 3-7 were synthesized in a similar manner (see Supplemental Information). Trisaccharide 2b with an aminopentyl linker was synthesized using automated glycan assembly (Weishaupt et al., 2016) .
Analysis of Monoclonal Antibodies and Hyper Immune Sera against ST3-CPS by Glycan Array Screening
Sera and antibodies against the native antigen were analyzed to identify key antigenic components that are recognized by the immune system. Glycan arrays containing the synthetic ST3 carbohydrate antigens 1-7 as well as ST3-CPS were used to screen monoclonal antibodies (mAbs) and polyclonal hyper immune serum for epitope mapping (Geissner et al., 2014) . Pooled sera of individuals who received the polysaccharide vaccine Pneumovax 23 contain antibodies that bind tetrasaccharides 1 and 2b ( Figure S2 ) (Goldblatt et al., 2011) . Two protective mAbs, 1E2 and 5F6, that had been raised against ST3 CPS were found to bind ST3 CPS on the glycan array ( Figure 3 ) (Tian et al., 2009) . Both antibodies bound tetrasaccharide 1 better than any of the smaller synthetic glycans; however, the mAbs differed in binding to trisaccharides 2a and 3. Apparently, distinct and shifted epitopes are being recognized by the two antibodies that differ from the known cellubiuronic acid minimal protective ST3 epitope as none of the disaccharides on the array were recognized (Benaissa-Trouw et al., 2001) . Tetrasaccharide 1 contains the protective epitope of both mAbs and was selected for further immunogenicity studies. Glycan array screening of polyclonal and mAbs recently allowed us to identify a lead tetrasaccharide glycotope for S. pneumoniae serotype 8 (ST8) that also presents a capsule lacking non-mammalian monosaccharides (B.S. et al., unpublished data). The glycan array screening approach therefore seems to be widely applicable for this type of CPS antigens.
Preparation and Characterization of ST3 Tetrasaccharide 1-CRM197 Glycoconjugates
Carbohydrates generally act as T cell-independent B cell antigens (Brodeur and Wortis, 1980; Mond et al., 1995) . Covalent attachment of carbohydrate antigens to carrier proteins produces neoglycoconjugates that, unlike native carbohydrates, induce a T cell-dependent immune response (Avery and Goebel, 1931; Pozsgay, 2000) . Synthetic tetrasaccharide 1 was conjugated to the carrier protein CRM197, a widely used detoxified mutant of diphtheria toxin that is a constituent of licensed vaccines and induces little carriermediated suppression of antihapten responses (Tontini et al., 2013; Pecetta et al., 2015 Pecetta et al., , 2016 . Di-(Nsuccinimidyl) adipate (DSAP) was used as the crosslinker. The amine group of the linker in tetrasaccharide 1 was reacted with one N-hydroxysuccinimide (NHS) ester present in DSAP to form the spacer-appended oligosaccharide ( Figure 4A ). Unreacted DSAP was subsequently extracted with chloroform. The neoglycoconjugate was formed by coupling the spacer-activated glycan with the amino groups of the lysines present in CRM197. Coupling was confirmed by SDS-PAGE. MALDI-TOF mass spectrometry (MS) revealed that on average four to six oligosaccharide haptens were loaded on each CRM197 molecule ( Figure S3 ). The oligosaccharide/protein ratio is an important immunogenicity determinant of glycoconjugates, and effects of loading on our antigen will eventually have to be determined, but no loading effects for ST3 oligosaccharides obtained by depolymerization of native CPS have been observed (Laferrière et al., 1997) . A recent detailed MS analysis identified the surface amine groups that were preferentially modified on CRM197 (Möginger et al., 2016) .
Immunogenicity Evaluation of Glycoconjugates
To test the immunogenicity of tetrasaccharide hapten 1, six female C57BL/6 mice per group were each immunized subcutaneously (s.c.) 28 days apart with two doses of glycoconjugate 1-CRM197 formulated either with Freund's adjuvant (FA) or Alum (Alhydrogel, aluminum hydroxide). Aluminum hydroxide was preferred over aluminum phosphate that is part of approved glycoconjugate vaccines due to its positive charge at neutral pH allowing better absorption of the CRM modified with the negatively charged ST3 oligosaccharides (Lindblad, 2004) . Each dose contained 5 µg of tetrasaccharide 1. Control animals received PBS. The anti-hapten 1 antibody titers were monitored using glycan array analysis. The immunized mice elicited immunoglobulin G (IgG) antibodies that specifically bound to tetrasaccharide 1, demonstrating that hapten 1 is immunogenic ( Figure 4C ). Isotype switching to IgG and boosting effects indicated a T celldependent immune response ( Figures 4C and 4D ). The serum from immunized mice reacted against both the carrier protein as well as the glycoconjugate spacer ( Figure 4C ), possibly due to some lysine residues modified only with the spacer (Möginger et al., 2016) . Serum antibody titers against ST3-CPS from immunized mice were measured by ELISA using purified ST3-CPS as the coating antigen. Antibodies raised against synthetic hapten 1 significantly cross-reacted with the natural ST3-CPS, thus highlighting the vaccine potential of hapten 1 ( Figure 4D ). The immunogenicity of tetrasaccharide 1 was strongly dependent on the adjuvant formulation. Conjugates formulated in FA induced higher antibody titers in mice compared with Alum-formulated conjugates ( Figure 4D ).
Protective Effects of the ST3 Tetrasaccharide 1-CRM197 Conjugate
Protective antibodies often function by opsonization and promotion of complement-mediated lysis of target pathogens (Romero-Steiner et al., 2006; Tian et al., 2009 ). Therefore, we tested sera from 1-CRM197-immunized mice for their opsonophagocytic potential in a standardized opsonophagocytosis assay (OPA) (Johnson et al., 1999; Romero-Steiner et al., 2006) . Human promyelocytic leukemia cells (HL-60) were differentiated into neutrophil-like cells in the presence of dimethylformamide for 6-7 days. Next, ST3 (PN36, strain NCTC7978) were incubated with test sera from naive (pre-immune) or 1-CRM197-immunized mice and then added to differentiated HL-60 cells in the presence of complement. After 1 hr, the remaining viable S. pneumoniae were quantified by plating and subsequent counting of colonies (colony-forming unit [CFU] assay). Serum from 1-CRM197-immunized mice mediated dose-dependent killing of pneumococci, demonstrating that the synthetic conjugate vaccine elicited opsonophagocytic antibodies ( Figure 5 ). OPA titers of R1:8 are considered efficient in individuals immunized with existing 7-or 13-valent conjugate vaccines (Schuerman et al., 2011; Song et al., 2013) . Anti-pneumococcal serum antibody titers as well as opsonophagocytic activity were strongly dependent on the adjuvant used for formulation. FA elicited higher antibody titers ( Figure 4D ) with higher killing activity in the OPA assay ( Figure 5 ) compared with Alum-adjuvanted 1-CRM197 glycoconjugate.
Having established 1-CRM197 glycoconjugate immunogenicity, we next evaluated its immunoprotective properties against pneumococcal pneumonia in an established mouse model (Reppe et al., 2009; Witzenrath et al., 2011) . As FA is not suitable for vaccine use, we administered the glycoconjugate formulated with Alum or unadjuvanted. Alum (aluminum phosphate) is the adjuvant in current commercial pneumococcal conjugate vaccines such as PCV13. Mice were immunized three times (days 0, 14, and 28) with 1-CRM197 containing 5 μg of tetrasaccharide 1 per dose and antibody titers were measured ( Figure  4E ). Naive and 1-CRM197-immunized C57BL/6 mice were infected transnasally on day 35 with 1x3 10 6 CFU S. pneumoniae (PN36, NCTC 7978) and clinical signs of disease (weight loss, body temperature) were monitored over the course of 48 hr. Immunization with Alum-adjuvanted 1-CRM197 significantly reduced disease activity as evidenced by a less pronounced drop in body temperature and lower weight loss ( Figures 6A and 6B) . As a surrogate for organ damage and barrier disruption, we measured pneumoniainduced lung permeability. Whereas pneumococcal pneumonia strongly increased lung permeability in naive and 1-CRM197-immunized mice, vaccination with 1-CRM197 adjuvanted with Alum preserved alveolar barrier integrity, demonstrated by low albumin bronchoalveolar lavage fluid (BALF)/plasma ratio ( Figure 6C ).
As a direct indicator of antibacterial defense in naive and immunized mice, we quantified bacterial burdens 48 hr postinfection to assess the protective effects of 1-CRM197 immunization on bacterial growth. Immunization with 1-CRM197 and Alum significantly reduced pulmonary bacterial loads when compared with PBS-treated mice or animals immunized with the glycoconjugate without adjuvant ( Figure 7A ). Moreover, immunization almost completely prevented the bacteremia that was frequently observed in vaccine-naive control animals ( Figure 7B ). The improved antibacterial defense was accompanied by increased lymphocyte numbers ( Figure S5 ) and reduced cytokine levels ( Figure S6 ) in the alveolar compartment of S. pneumoniae-infected mice. These results provide a solid proof-of-concept for the efficiency of a semi-synthetic pneumococcal carbohydrate conjugate vaccine strategy against ST3.
Induction of long-lived immunity is an important feature of successful vaccination. Therefore, we assessed long-term effects of ST3-tetrasaccharide immunization. In contrast to the robust protection at 35 days post-immunization, we observed minor effects 4 months after the initial vaccination ( Figures 7C and 7D) , which is being evaluated further and will be reported elsewhere. The deficiency of the synthetic ST3-tetrasaccharide vaccine to generate long-lasting immunity may not be a matter of antigenic potential, even though only a small tetrasaccharide antigen was employed as hapten. More studies have suggested morbidity and mortality, particularly in toddlers and elderly people. While current pneumococcal conjugate vaccines protect against severe infections induced by most of the included serotypes, the immune response against serotype 3 is often too low for efficient immunoprotection. Alternative approaches are needed to improve vaccines for this highly invasive pneumococcal serotype. One promising strategy involves replacement of the ill-defined isolated polysaccharides in current vaccines with synthetic designer carbohydrate antigens. We show that glycoconjugates of a synthetic carbohydrate antigen can confer protection against serotype 3 in a mouse model of pneumococcal that tetrasaccharides or smaller glycans are enough to elicit protective immunity, such as for Neisseria meningitidis serogroup W135 (Wang et al., 2013) as well as S. pneumoniae serotypes 6 (Jansen et al., 2001 ) and 14 (Safari et al., 2008) , but longterm memory is not regularly tested. However, sometimes larger glycans seem to be necessary, as devised in case of lipopolysaccharide O-antigens of Salmonella typhimurium O12 (Svenson and Lindberg, 1981) and Shigella flexneri serotype 2a (Phalipon et al., 2006) . In addition, oligosaccharides can be fine-tuned for ideal antigenicity by minor structural modifications compared with the natural sequence as we have recently shown for an ST8 tetrasaccharide hapten (B.S. et al., unpublished data). Carbohydrates generally elicit a weaker immunity when compared to peptide antigens. Studies on Prevnar 13 and during the development of Synflorix showed that ST3 is an especially challenging pneumococcal serotype to achieve high titers and memory even when conjugates of the large purified polysaccharide are injected (Poolman et al., 2009; Gruber et al., 2012; Prymula and Schuerman, 2014) . Rather than using larger antigens, formulation effects such as antigen loading, carrier protein, and adjuvant adjustment to mobilize protective T cell and subsequent B cell memory responses may be required to increase the immunogenicity of semi-synthetic glycoconjugate vaccines (Snippe et al., 1983; Sander, 2012) . Having a protective synthetic oligosaccharide lead antigen in hand will allow in-depth studies for hapten and formulation optimization.
In summary, we demonstrate that synthetic ST3 tetrasaccharide-conjugates are viable vaccine candidates to protect from bacterial pneumonia. The formulation including the employed adjuvants of the semisynthetic vaccine needs further refinement to achieve long-lived immune memory. Activation of innate immune responses capable of instructing robust adaptive immunity may be crucial in this regard (Blander and Sander, 2012; Sander, 2012) .
SIGNIFICANCE
Pneumonia and other invasive infections induced by Streptococcus pneumoniae are associated with significant morbidity and mortality, particularly in toddlers and elderly people. While current pneumococcal conjugate vaccines protect against severe infections induced by most of the included serotypes, the immune response against serotype 3 is often too low for efficient immunoprotection. Alternative approaches are needed to improve vaccines for this highly invasive pneumococcal serotype. One promising strategy involves replacement of the ill-defined isolated polysaccharides in current vaccines with synthetic designer carbohydrate antigens. We show that glycoconjugates of a synthetic carbohydrate antigen can confer protection against serotype 3 in a mouse model of pneumococcal pneumonia, the most common form of pneumococcal infection. The investigated glycan structure, its glycoconjugates and formulation can be optimized and refined to newly establish semi-synthetic and fully synthetic vaccine candidates with the potential to overcome the limitations of the currently used pneumococcal glycoconjugates. This study is therefore an important step toward improving the efficacy and availability of pneumococcal conjugate vaccines.
EXPERIMENTAL PROCEDURES
This section gives an overview of the methods used in this study. Detailed experimental procedures can be found in the Supplemental Information.
Glycan Arrays
Glycan arrays were obtained by robotically spotting carbohydrates onto CodeLink NHS-activated glass slides (SurModics) using an S3 microarray printer (Scienion) as described previously Reinhardt et al., 2015; Geissner et al., 2016) . Printing patterns are described in Figures S1 and S4. Slides were incubated overnight at high humidity, quenched, and stored dry until use. Before the assay, slides were blocked with 1% BSA-PBS. After drying, a 64-well incubation grid (Grace Bio-Labs) was attached and the primary antibody or serum diluted in 1% BSA-PBS was applied to individual wells. After incubation and washing, dilutions of secondary antibodies were applied. Following incubation, washing, and drying, slides were scanned with a 4300A microarray scanner (Molecular Devices).
Preparation of Neoglycoconjugates
Neoglycoconjugates of 1-CRM197 were prepared as described previously (Anish et al., 2013a (Anish et al., , 2013b . Tetrasaccharide 1 was reacted with di-(N-succinimidyl) adipate in DMSO catalyzed by triethylamine for 2 hr at room temperature. Addition of coupling buffer (100 mM sodium phosphate buffer [pH 7.5]) and extraction of unreacted linker with chloroform was followed by reaction of linker-appended tetrasaccharide with recombinant CRM197 (Pfenex) overnight in coupling buffer. After desalting with 10 kDa Amicon ultrafiltration devices (Millipore), neoglycoconjugates were characterized by SDS-PAGE and MALDI-TOF MS.
ELISA
Antibody titers were determined on Immulon HBX (Thermo Scientific) high binding plates coated with isolated ST3 CPS (SSI Diagnostica) and blocked with 1% BSA-PBS. Subsequently, plates were incubated with the serum diluted in 1% BSA-PBS, washed, incubated with goat anti-mouse IgG horseradish peroxidase (Dianova) diluted 1:10,000, and washed and incubated with 1-Step Ultra TMB (Thermo Scientific). After stopping the reaction with 2% sulfuric acid, absorbance at 450 nm was determined.
Immunizations and Challenge
All animal experiments were approved by the institutional and regulatory authorities and conducted according to the legal regulations. In the pre-study, six female C57BL/6 mice (Charles River) per group were immunized twice s.c. with 1-CRM197 containing 5 μg tetrasaccharide 1 formulated either with Alum (Alhydrogel, Brenntag) or FA (Sigma-Aldrich; complete FA for priming, incomplete FA for boosting). Primary and boosting immunizations were 28 days apart. Serum samples were taken regularly to follow immunization success.
For the short-term challenge study, female C57BL/6N mice (n = 10-11 per group, 8 weeks, Charles River) were immunized s.c. with 1-CRM197 containing 5 μg tetrasaccharide formulated with or without Alhydrogel (Alum) at a total volume of 100 μL. Control mice received 100 μL of sterile PBS s.c. Booster doses were given on days 14 and 28. Blood (20 μL) for serum separation was collected from the tail vein on days 14 and 28. For the long-term challenge study, mice (n = 11 per group) were immunized s.c. with Alhydrogel alone, 1-CRM197 containing 5 μg tetrasaccharide formulated with Alhydrogel or PBS (control) at a total volume of 100 μL on days 0, 14, and 28. Serum was collected on days 0 and 35.
OPA
HL-60 cells differentiated to pseudogranulocytes were resuspended in Hank's buffer without Ca 2+ or Mg 2+ (OPA buffer) to an effector-to-target cell ratio of 400:1 and kept in an ice bath until used. For the assay, 5 μL aliquots of serum (run in quadruplicate for each assay) were added to the OPA buffer in a microtiter plate and serially diluted for a titer range of 1:32 to 1:4,096. Twenty microliters of S. pneumoniae suspension (serotype 3, strain NCTC7978) taken directly from thawed cryostocks was added to each well. The plate was then incubated for 15 min at 37 °C and 5% CO 2 . Phagocytosis was then initiated by addition of 10 μL baby rabbit complement (Cedar Lane/BIOZOL) to each well, followed immediately by 40 μL of differentiated HL-60 cells. After incubation for 45 min at 37 °C in a horizontal shaker (220 rpm), the plate was kept on ice and 5 μL of suspension from each condition was plated onto 5% sheep blood agar plates and incubated for 10-12 hr at 37 °C to manually count CFUs.
Challenge
In pneumococcal challenge experiments analyzing bacterial elimination, pulmonary barrier dysfunction, and inflammation, a total of seven to eight mice per immunized group were anesthetized intraperitoneally with ketamine (80 mg/kg, Ketavet, Pfizer) and xylazine (25 mg/kg, Rompun, Bayer) on days 35 (short-term effect) or 112 (long-term effect) and were transnasally infected with 1 3 106 CFU S. pneumoniae (serotype 3, strain NCTC7978) in 20 μL PBS as described previously (Schmeck et al., 2004; Witzenrath et al., 2006) . Control mice received 20 μL PBS transnasally. Health status was monitored at 12 hr intervals post-infection.
Dissection and Sampling
Forty-eight hours post-infection, mice were anesthetized with ketamine (160 mg/kg) and xylazine (75 mg/kg), intubated, ventilated and heparinized (Dames et al., 2014) , and blood was drawn from the inferior vena cava. Lungs were flushed with 0.9% saline via the pulmonary artery. BAL was performed twice using 800 μL PBS and lungs were removed.
Bacterial Burden in Lung Tissue and Blood
Serial dilutions of homogenized lungs and blood were plated on blood agar and incubated at 37 °C under 5% CO 2 for 24 hr to count CFUs.
Albumin ELISA
BALF supernatant and plasma albumin concentrations were measured by ELISA (Bethyl Laboratories) according to the manufacturer's instructions. Alveolar edema formation was assessed by calculating the albumin BALF/ plasma ratio.
Statistical Analysis
Data are expressed as mean + SEM or scatterplots and mean. Monoclonal antibody analysis: two-way ANOVA with post hoc pairwise Bonferroni comparison was performed using GraphPad Prism 5. Challenge studies: one-way ANOVA followed by Dunn's post hoc test were performed using GraphPad Prism 4.02 software. *p < 0.05, **p < 0.01, and ***p < 0.001 were considered to be significant. TMSOTf, trimethylsilyl trifluoromethanesulfonate; DCM, dichloromethane; NIS, N-iodosuccinimide; TfOH, trifluoromethanesulfonic acid; HF, hydrofluoric acid; Py, pyridine; BzCl, benzoylchloride; PTSA, p-toluenesulfonic acid; EtSH, ethanethiol; BAIB, bis(acetoxy)iodobenzene; TEMPO, 2,2,6,6-tetramethylpiperidine 1-oxyl; NaOMe, sodium methoxide. Mice were immunized with PBS, Alum, or 1-CRM197 formulated with Alum s.c. on days 0, 14, and 28. Mice were bled on day 35 for serum collection and OPA titers were determined. Values from three independent experiments with pooled sera are given as mean and SEM. OPA titers using sera of mice that received two doses of 1-CRM197 formulated with FA in the pre-study (no replicates) were included for comparison. Body temperature (n = 7-8), (B) body weight (n = 7-8), and (C) lung permeability (n = 6-8) were assessed 48 hr after infection. *p < 0.05, **p < 0.01 and ***p < 0.001 from Dunn's post hoc test after one-way ANOVA were considered to be significant.
SUPPLEMENTAL INFORMATION
Effects, 5 Weeks after Initial and Effects, 4 Months after Initial on Pneumonia (A and B) Mice were immunized s.c. on days 0, 14, and 28, and were transnasally infected with 1 x 10 6 CFU S. pneumoniae on day 35. Bacterial burden was assessed in lung tissue (A) and blood (B) 48 hr post-infection (n = 8). Pulmonary leukocyte recruitment and cytokine release in S. pneumoniae-infected lungs are shown in Figures S5 and S6 , respectively. (C and D) Mice immunized on days 0, 14, and 28 were transnasally infected with 1 x 10 6 CFU S. pneumoniae 112 days after initial immunization. Bacterial burden was assessed in lung tissue (C) and blood (D) 48 hr post-infection (n = 6-8). *p < 0.05 and **p < 0.01 from Dunn's post hoc test after one-way ANOVA were considered to be significant.
